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Abstract: Background: Microbeam Radiation Therapy (MRT) is an innovative approach in radiation
oncology where a collimator subdivides the homogeneous radiation field into an array of co-planar,
high-dose beams which are tens of micrometres wide and separated by a few hundred micrometres.
Objective: This scoping review was conducted to map the available evidence and provide
a comprehensive overview of the similarities, differences, and outcomes of all experiments that have
employed animal models in MRT. Methods: We considered articles that employed animal models
for the purpose of studying the effects of MRT. We searched in seven databases for published and
unpublished literature. Two independent reviewers screened citations for inclusion. Data extraction
was done by three reviewers. Results: After screening 5688 citations and 159 full-text papers, 95 articles
were included, of which 72 were experimental articles. Here we present the animal models and
pre-clinical radiation parameters employed in the existing MRT literature according to their use
in cancer treatment, non-neoplastic diseases, or normal tissue studies. Conclusions: The study of
MRT is concentrated in brain-related diseases performed mostly in rat models. An appropriate
comparison between MRT and conventional radiotherapy (instead of synchrotron broad beam) is
needed. Recommendations are provided for future studies involving MRT.
Keywords: microbeam radiation therapy; scoping review; animal models; rat; mouse; synchrotron;
spatial fractionation; radiotherapy; oncology
1. Introduction
1.1. Background
In our society, cancer is an increasingly prevalent and therapeutically challenging disease.
Of all cancer patients treated curatively, half will receive radiation therapy [1]. However, despite these
efforts, more than a quarter of a million people die from cancer in the EU annually [2]. The main factor
limiting conventional radiotherapy (RT) is the toxicity induced in vital surrounding healthy tissues,
which constrains dose-escalation and effective tumour control [3]. Synchrotron X-ray microbeams have
been recognized as a unique tool to overcome this limitation [4], eliciting scientific interest across the
world in a radio-therapeutic application known as Microbeam Radiation Therapy (MRT). MRT consists
of a spatially-modulated, co-planar array of low energy X-rays delivered to tumours [5]. These spatially
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fractionated beams exploit the dose-volume effect for extraordinary normal tissue tolerance [6] and
trigger a cascade of biological effects that greatly improve tumour control [7].
1.2. Rationale
In the last few decades, MRT research has expanded to include several synchrotron and
non-synchrotron sources around the world. The progress, however, has been relatively slow.
A significant challenge for MRT is the wide range of modifiable radiation parameters which can
profoundly impact its radiobiological effects, and ultimately, treatment outcomes. Research groups have
explored these radiation parameters using various rodent and non-rodent animal models. However,
there remains no clear consensus within the community on the optimal MRT parameters and strategy
for cancer therapy, delaying translation to human clinical trials. Comprehensively evaluating the
existing literature is essential to unifying these pre-clinical data and strategically promoting future
research to support clinical translation.
1.3. Objective
The objective of this scoping review is to map the available evidence and provide an overview of
the similarities, differences, and outcomes of all experiments that have employed animal models in
MRT. The aim is to inform the community about progress made in the field of MRT and to identify
existing gaps in current research.
2. Methods
2.1. Protocol and Registration
Our protocol was developed according to the scoping review methodological framework proposed
by the Joanna Briggs Institute [8], and refined by two methodological papers on how to conduct
scoping reviews published by Peters at al. [9] and Tricco et al. [10]. The draft protocol was revised
by the research team of the Institute of Anatomy of the University of Bern and by the information
specialist of the University of Bern’s Medical Library. The protocol could not be registered in the
International Prospective Register of Systematic Reviews (PROSPERO), as this is not yet an option
for scoping reviews. This scoping review was written according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)-update for Scoping Reviews [11].
2.2. Eligibility Criteria
The review considered articles that employed animal models with the purpose of studying the
normal tissue or therapeutic effects of MRT. We included all papers that employed MRT as (i) an array
of co-planar microbeams, (ii) from any radiation source (synchrotron and non-synchrotron) and quality
(photons, protons, and others), (iii) that were applied to animals. We defined MRT as an array of
co-planar microbeams of widths equal to or lower than 100 µm, which are spaced by a few hundred
micrometres within the array. This definition of MRT has been used by other research groups, and it
is becoming the standard in the field [5,12–15]. MRT is also described as spatial fractionation of the
radiation beam, which is the main difference with conventional radiotherapy (Figure 1). We excluded
papers that employed minibeams because their width exceeds 100 µm. We also excluded publications
that employed a single microbeam and a microbeam scanning technique because these approaches do
not qualify as spatial fractionation.
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Figure 1. Homogenous radiation vs spatial fractionation. Schematic representation of a homogenous 
beam of radiation (panel A) and a MRT array (panel B) targeting a malignancy. Schematic 
representation of the microbeams dose distribution (panel C). 
Figure 1. Homogenous radiation vs s ti ti . Schematic represen ation of a homogenous
beam of radiation (panel A) and a MRT rray (panel B) targ ting a malig ancy. Schematic representation
of the microbeams dose distribution (panel C).
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2.3. Information Sources
Literature searches were performed by an information specialist (HJ) in the following
information sources:
• Medline (Ovid) (incl. Epub Ahead of Print, In-Process and Other Non-Indexed Citations,
Medline Daily and Ovid Medline Versions (1946–October 02, 2019)
• Embase (Ovid) (1947–October 02, 2019)
• Cochrane Library (1996–October 02, 2019)
• Scopus (1788–October 02, 2019)
• ICTRP Trial Register (WHO)
• ClinicalTrials.gov
• Livivo Search portal
2.4. Search Strategy
An initial search strategy in Medline was drafted and tested against a list of core references to
see if they were included in the search results. After refinement and consultation with the research
team, search strategies were set up for each information source, based on database-specific, controlled
vocabulary and text words. No limits have been applied in any database considering study types,
languages, publication years, etc. Beside standard bibliographic databases for medical journals like
Medline, Embase and the Cochrane Library, two interdisciplinary databases, Scopus and Livivo,
have been selected to search for other publications types than journal articles (e.g., conference
proceedings, book series, publications from university repositories). All searches were run on October
3rd, 2019. In addition to electronic database searching, bibliographies and reference lists from relevant
publications were checked.
For our search strategy, we decided not to focus on any particular animal species or animal models.
This allowed for maximum sensitivity in the search and ensured that publications on all organisms
on which MRT had been applied were included in our search results. Therefore, our search strategy
focused only on the concepts of “microbeam radiation therapy”, “synchrotron x-ray microbeams”
in combination with “radiotherapy”, “therapy” or similar terms. The detailed search strategies are
presented in Supplementary Materials.
2.5. Selection of Sources of Evidence
All identified citations were collated, loaded into EndNote and duplicates were removed.
The collection was then uploaded into the software Rayyan [16]. Two independent reviewers performed
the first level screening of titles and abstracts against the inclusion criteria. Two reviewers also performed
the second level of full-text screening.
2.6. Data Charting and Synthesis of Results
Three reviewers determined the variables to extract. The studies were charted jointly by using
Microsoft Excel Online. We grouped the studies into experimental articles, reviews, clinical perspectives,
reports, commentaries, and Letters to the Editor. Reviews, commentaries, and clinical perspectives
were used to screen for possibly missing citations. The experimental articles and reports were charted.
3. Results
3.1. Literature Selection
After duplicates were removed, a total of 5688 records were identified (Figure 2). Based on title
and abstract screening, 5534 citations were excluded, and 159 potentially relevant papers were assessed
for full-text eligibility, which includes 5 additional records identified through reference scanning.
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After the full-text screening, 64 articles were further excluded, and 95 studies were finally included in
the review. The list of included references can be found in the Supplementary Materials.
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3.2. Study Characteristics
The 95 pa ers tudying animal models i e inated betw en 1994 and 2019
(Figure 3A). The majority of the articles have bee i the last ten years, with the highest
publication record (11 papers) in 2015. Fro the 7 tal articles, the most co monly used
animal models have been Rats (59.7%) and ic ( . ) it ly a few studies using other animal
models (Figure 3B).
3.3. Technical Parameters
In the reviewed literature, the MRT array was created via two mechanisms. By performing several
consecutive irradiations (with horizontal translation) using a single-slit collimator, to generate an array
of co-planar microbeams at the target. Alternatively, by using a multi-slit collimator that generates an
array of co-planar microbeams simultaneously.
Across the included literature, the width of the microbeams ranged from 20 to 100µm, with spacing
varying from 50 up to 500µm (See Table 1; Table 2).
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MRT can be delivered as a single or multiple array(s). When multiple arrays are delivered,
the irradiation geometry can be subclassified according to the trajectory of delivery and the
anatomical plane.
• Trajectory of delivery: if two or more arrays were delivered in the same trajectory or direction,
they were called unidirectional. However, if the arrays were delivered in two or more trajectories,
they were referred to as bidirectional or multidirectional.
• Anatomical plane: if two or more MRT arrays were delivered in the same anatomical plane they
were also called co-planar. When two co-planar arrays were delivered without overlap of the
peak-dose regions, they were referred to as interlaced. Delivery in different planes was referred
to as cross-planar where irradiation with a single unidirectional MRT array was followed by
a rotation of the animal and a second (or third) MRT array was delivered (creating a grid-like
pattern in the target volume). When arrays in this manner intersect at 90◦, they are orthogonal
(irrespective of the anatomical plane or trajectory).
The use of the word cross-fired however, was more general. It described two or more arrays, but it
did not inform consistently about the trajectory or the anatomical plane of the arrays.
Peak-doses ranged from 3.9 Gy [17] up to 10000 Gy [18], however, the depth at which they were
measured varied across the publications from 0.3 mm (skin-entry or entrance) to several millimetres in
depth depending on the location of the target. Valley-doses were also reported at different depths,
the lowest was 0.5 Gy at skin-entry [19], and the highest was 38.5 Gy at 5 mm depth [20]. Additionally,
the peak-to-valley dose ratio (PVDR) was described as an important metric related to the therapeutic
index of MRT [21].
Dose-rate was reported in only 27 out of 72 experimental articles and varied greatly from
0.3 to 16,000 Gy/s. This large variation is rel vant becau dose-rate, together with the peak-dose,
will determine whether MRT will also have a FLASH effect. The FLASH effect is defined as the de ivery
of radiation at u tra-high dose rates, which allows normal tissue olerance levels to be exceeded [22–24].
This is achieved when the whole dose of radiation (the peak-dose in the case of MRT) is delivered in
less than 200 milliseconds [24]. Therefore, not all MRT sources will be able to have a FLASH effect since,
for example, the delivery of a peak-dose of 400 Gy requires a dose rate of 2000 Gy/s as a minimum to
be delivered in 200 milliseconds.
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3.4. Animal Models in MRT
Animal models are divided into their use for investigating tumour control, non-neoplastic diseases
and normal tissue effects following MRT.
3.4.1. MRT for Cancer
Table 1 reports all the studies that involve the use of MRT to treat tumour-bearing animals and
summarises key radiation parameters which are associated with tumour control.
3.4.2. Glioma
The most commonly employed cancer models in MRT research were brain tumours.
The first animal model used was syngeneic 9L gliosarcoma (9LGS) implanted in rats. In the early
nineties, at the National Synchrotron Light Source of the Brookhaven National Laboratory, Laissue,
Slatkin and colleagues [25–28] showed that MRT (unidirectional and bidirectional) delayed tumour
growth of intracerebral 9LGS. Since then, 9LGS cells in the Fisher 344 strain rat model has been widely
used to test several MRT configurations and doses.
In 2002, Dilmanian and colleagues [15] studied different unidirectional arrays on the same 9LGS
model. The array had a constant microbeam width (27 µm), three spacings (50 µm, 75 µm and 100 µm),
and two peak-doses (150 Gy and 500 Gy). All MRT conditions improved survival as compared to the
control group.
In addition, several studies conducted by Bouchet and colleagues [20,29,30], using the 9LGS model,
investigated the molecular mechanisms behind the MRT efficacy in comparison to unirradiated controls.
A comparison between a homogenous broad beam (BB) of radiation delivering 17.9 Gy to the
tumour with one MRT array - formed by microbeams of 50 µm width and centre-to-centre spacing of
200 µm (hereafter defined as “50 µm; 200 ctc”) - delivering 200 Gy peak-doses to the tumour revealed
that the survival for the animals of both groups was similar [31]. However, when the deposited
peak-dose in the MRT array was increased to 400 Gy the survival of the gliosarcoma-bearing rats was
significantly increased compared to the BB irradiated animals [31].
Several studies have shown that delivering multiple MRT arrays increased the survival of
9LGS-bearing rats significantly compared with unirradiated controls [32], with characteristic induction
of hypoxia at the tumour site [33]. Serduc et al. [34] employed bidirectional MRT arrays to compare the
efficacy of three different microbeams widths (25, 50 and 75 µm), each delivered as two orthogonally
cross-planar intersecting arrays. In all the MRT configurations the valley-dose was kept constant
(at 18 Gy each) by fixing the spacing (211 ctc), and only the peak-dose and the microbeam widths were
modified. Thus, microbeams of 25, 50, and 75 µm of width, had peak-dose of 860 Gy, 480 Gy, and 320 Gy
per array, respectively. All MRT groups delayed the 9LGS tumour growth. The bidirectional MRT of
50 µm 211 ctc had the best therapeutic index, while the bidirectional MRT of 25 µm, 211 ctc caused
early deaths in 50% of cases four days after irradiation.
Three cross-planar MRT arrays (orthogonal to each other) were used to target 9LGS-bearing rats
in three consecutive days at the European Synchrotron [35]. Briefly, day 1 (25 µm; 211 ctc; 400 Gy),
day 2 (25 µm; 211 ctc; 360 Gy), and day 3 (25 µm; 211 ctc; 400 Gy). This strategy increased the lifespan
of the 9LGS-bearing rats by 216% in comparison to the control group.
MRT has also been tested on 9LGS in combination with different therapeutic agents. In a study
by Régnard and colleagues [36], MRT (25 µm; 200 ctc; 625 Gy peak-dose) was combined with direct
intra-tumoral injection of the chemotherapeutic agents’ Temozolomide, Cisplatin, or the contrast
agent Gadolinium. Combining Temozolomide and Cisplatin with MRT did not improve survival.
However, the concomitant administration of Gadolinium, as a result of radiation dose-enhancement,
did. The antimitotic drug Chalcone JAI-51 (an inhibitor of tubulin polymerization) improved survival
of 9LGS-bearing rats when combined with two orthogonally cross-fired MRT arrays (50 µm; 200ctc;
480 Gy peak-dose) [37]. Furthermore, Sorafenib (an anti-angiogenic drug) was tested in combination
Cancers 2020, 12, 527 8 of 26
with MRT on the same cancer model [38]. Although the tumour growth rate was similar after MRT and
the MRT+Sorafenib groups, there were appreciable changes in the tumour physiology which included
reduced tumour blood volume after MRT+Sorafenib.
A study from 2006 shed light on the possible synergistic action between MRT and the immune
system [39] where combining MRT (27 µm; 211 ctc; 625 Gy peak-dose) with injections of irradiated
9LGS cells (transfected with the gene GM-CSF), increased the median survival of 9LGS-bearing rats.
Other types of glioma cell lines have also been exposed to MRT. F98 glioma cells and
C6 cells, implanted respectively in Wistar and Fisher rats, were used to demonstrate that two
orthogonal, cross-planar MRT arrays (24.75 µm; 211 ctc; 350 Gy peak-dose) significantly increased
survival as compared to untreated controls [40]. This effect was amplified when MRT was
preceded by the administration of the glutathione synthesis inhibitor buthionine-SR-sulfoximine [41].
When two orthogonal MRTs (50 µm; 200 ctc; 241 Gy peak-dose and 10.5 Gy valley-dose) were compared
to two orthogonal BB fields (10.5 Gy), MRT was more effective than BB in slowing F98 glioma growth
and increasing tumour vessel permeability [42]. The same model of F98 cells in rats was employed by
Fernandez-Palomo and colleagues, to prove that the presence of glioma causes different abscopal and
bystander effects in MRT-irradiated rats and also in unirradiated (tumour-free) cage-mate rats [43].
C6 glioma-bearing rats were also employed by Fernandez-Palomo et al. for the study of bystander
and abscopal effects when comparing MRT with BB [19]; both MRT and BB promoted radiation-induced
bystander effects in the non-irradiated portion of the brain and in the bladder of the tumour-bearing
animals. This same model has been used to study the dose deposition of MRT (25 µm; 200 ctc; at 35, 70
or 350 Gy peak-dose) using the marker of DNA damage γ-H2AX [44]. Moreover, the damage of the
optic nerve was studied after treating the same C6 glioma in Wistar rat with cross-fired MRTs (25 µm;
200 ctc, 350 Gy peak-dose) [45]. The optic nerves did not show any significant histological difference
compared to unirradiated controls.
Rat xenografts of glioma cells implanted in the brain of nude mice were also used in MRT
studies. In a model of 9LGS cells implanted in nude mice (strain not reported), a significant increase of
tumoral apparent diffusion coefficient (ADC), consistent with an increase of vascular permeability,
was shown 24 h after the delivery of two orthogonally cross-planar MRT arrays (25 µm; 211 ctc; 500 Gy
peak-dose) in irradiated tumours versus unirradiated controls [46]. In addition, athymic nude mice
(Crl:NU-Foxn1nu) were implanted with F98 glioma cells to establish that bystander and abscopal effects
can also be detected in athymic mice after MRT irradiation (50 µm; 200 ctc; 22 or 110 Gy peak-dose) [47].
Finally, it must be mentioned that human xenografts in nude mice have also been explored. In the
study performed by Uyama and colleagues [48], U251 human glioma cells, implanted subcutaneously
into the flank of nude mice (BALB/cAJc1-nu/nu), were employed to successfully demonstrate the
efficacy of one MRT array (100 µm; 500 ctc; 124 Gy peak-dose) and two cross-planar, but unidirectional
MRT arrays of (100 µm; 500 ctc; 124 Gy peak-dose) or (20 µm; 100 ctc; 111 Gy peak-dose) at the SPring-8
Synchrotron radiation facility in Japan.
3.4.3. Mammary Tumours
Investigations of the effects of MRT on mammary malignancies have been made at the Japanese
and Australian Synchrotrons. The most used pre-clinical model for the study of MRT on mammary
malignancies is the subcutaneous injection of EMT-6.5 mouse mammary carcinoma cells in female
BALB/c mice. Dilmanian and colleagues [49] injected EMT6.5 cells subcutaneously in the flanks of mice
from which tumours were subsequently harvested and small portions transplanted subcutaneously into
the calves of BALB/c female mice. These mammary carcinoma-bearing mice were targeted with either
one MRT array (90 µm; 300 ctc; doses in Table 1), two cross-planar but unidirectional arrays (90 µm;
300 ctc; doses in Table 1), or with BB of either 23, 30, 38, or 45 Gy. They reported that even one array
can control EMT-6.5 tumour growth but that the cross-planar configuration optimally balances tumour
control and tissue toxicity.
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By subcutaneously inoculating EMT-6.5 and 67NR mammary tumour cells on the right hind leg of
BALB/c mice, Crosbie and colleagues [50] showed a significant increase in median survival compared
to controls following one MRT array (25 µm; 200 ctc, 560 Gy). They also showed no signs of tumour
re-growth after two different cross-fired MRT arrays (25 µm; 200 ctc; 280 Gy peak-dose) and (25 µm;
200 ctc; 560 Gy peak-dose).
Using the same syngeneic model, a comprehensive transcriptomic analysis of EMT-6.5 tumours,
exposed either to MRT (25µm; 200 ctc; 560 Gy peak-dose) or BB (11 or 22 Gy) compared to non-irradiated
tumour controls, underlined how MRT-treated tumours overexpress immune-related genes at early
time points after irradiation [51]. Similarly, MRT (25 µm; 200 ctc; 112 Gy or 560 Gy peak-dose) delivered
to EMT-6.5 tumours up-regulated genes that are involved in eosinophil recruitment and/or functionality
relative to BB (5 or 9 Gy) irradiated tumours [52]. Using the same EMT-6.5 mouse model and same
MRT and BB configurations and doses, Yang et al. [53] showed that a different immune response is
induced by MRT compared to BB, including a significant increase of tumour-infiltrating T-lymphocytes
at 48h post-MRT.
The tissue composition of the EMT6.5 mammary model was investigated after MRT (25 µm; 200 ctc;
560 Gy peak-dose) and BB (11, 22 or 44 Gy) using Fourier-transform infrared microspectroscopy [54].
Absorbance patterns in the nucleic acid region showed chemical shifts between the peak and valley-dose
regions [54].
Griffin et al. [55] employed a different type of syngeneic mouse model of mammary carcinoma,
where 4T1 cells were injected subcutaneously in the limb of female BALB/c mice. They combined MRT
with the anti-angiogenic peptide anginex and showed enhanced tumour growth-delay in combination
with MRT.
3.4.4. Melanoma
A recent publication from Potez et al. [7] described for the first time that MRT (50 µm; 200 ctc;
407.6 Gy peak-dose) is an efficient approach for the treatment of radioresistant melanomas compared
to a BB (6.2 Gy) irradiation and unirradiated control animals. In this model, B16-F10 melanoma cells
were implanted in the ears of C57BL/6J mice.
3.4.5. Squamous Cell Carcinoma
One study from Miura and colleagues [56] employed a murine model of aggressive murine
SCCVII squamous cell carcinomas implanted subcutaneously into the left thighs of female C3H mice.
They showed that a better palliative effect was elicited by MRT irradiations (35 µm; 200 ctc; 625 Gy or
884 Gy peak-dose and 70 µm; 200 ctc; 442 Gy peak-dose) compared to BB (25 or 35 Gy) irradiations.
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Table 1. MRT Parameters Used in Cancer Models.
Animal Cancer Type Number of Arrays
Microbeam Peak-dose (Gy) Valley-dose (Gy) Evaluated Criteria
Width (µm) Spacing (µm)
Rat [1] Gliosarcoma (9L) 1 & 2 50 200 400 entrance dose;350 @1cm depth 12.5 @1cm depth
Animal survival, tumour growth, tumour
vasculature, and cell proliferation
Rat [2] Gliosarcoma (9L) 2 50 200 480 entrance dose;418 @1cm depth 18.6 @1cm depth
Animal survival, cell cycle, and DNA
distribution patterns
Rat [3] Gliosarcoma (9L) 2 50 200 400 entrance dose;350 @1cm depth 12.5 @1cm depth
Tumour vasculature and tumour
oxygenation
Rat [4] Gliosarcoma (9L) 1 50 200 400 dose @tumour(i.e., @7mm depth)
18 dose @tumour
(i.e., @7mm depth) Animal survival and Transcriptomics
Rat [5] Gliosarcoma (9L) 1 50 200 400 dose @tumour(i.e., @7mm depth)
8 dose @tumour
(i.e., @7mm depth)
Tumour growth, transcriptomics, and
histopathology
Rat [6] Gliosarcoma (9L) 1 50 200
400 dose @tumour
(i.e., @7mm depth)
17.4 dose @tumour
(i.e., @7mm depth) Animal survival, tumour growth, cell
proliferation, and gene expression200 dose @tumour
(i.e., @7mm depth)
8.7 dose @tumour
(i.e., @7mm depth)
Rat [7] Glioma (F98) 2 50 200 241.4 entrance dose 10.5 @9mm depth Tumour vasculature and tumouroxygenation
Mouse [8] Mammary
(EMT6.5/67NR)
1
25 200
560 entrance dose 8.5 @centre of brain
Animal survival, DNA damage, cell
proliferation, and apoptosis
800 entrance dose 12 @centre of brain
2
280 entrance dose 8.5 @centre of brain
560 entrance dose 17 @centre of brain
Rat [9] Gliosarcoma (9L) 1 27
50
150 entrance dose;
108 @centre of brain 20 @centre of brain
Animal survival and histopathology
250 entrance dose;
179 @centre of brain 34 @centre of brain
300 entrance dose;
215 @centre of brain 40 @centre of brain
75
250 entrance dose;
179 @centre of brain 17 @centre of brain
300 entrance dose;
215 @centre of brain 20 @centre of brain
500 entrance dose;
359 @centre of brain 33 @centre of brain
100 500 entrance dose;359 @centre of brain 19 @centre of brain
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Table 1. Cont.
Animal Cancer Type Number of Arrays
Microbeam Peak-dose (Gy) Valley-dose (Gy) Evaluated Criteria
Width (µm) Spacing (µm)
Mouse [10] Mammary (EMT6.5)
1 90 300
800 dose @tumour 16 dose @tumour
Tumour ablation
890 dose @tumour 18 dose @tumour
970 dose @tumour 19 dose @tumour
1740 dose @tumour 35 dose @tumour
1820 dose @tumour 36 dose @tumour
1900 dose @tumour 38 dose @tumour
2 90 300
410 dose @tumour 16 dose @tumour
520 dose @tumour 21 dose @tumour
650 dose @tumour 26 dose @tumour
Rat [11] Glioma (C6) 1 25 200 17.5, 35, 70, 350entrance dose 0.51, 1.03, 2, 10.3
Bystander effects in-vivo by clonogenic cell
survival
Rat [12] Glioma (C6) 1 25 200 35, 70, 350 entrancedose NR DNA damage
Rat [13] Glioma (F98) 1 25 200 20, 200 entrance dose NR Bystander effects in-vivo by clonogenic cellsurvival and cellular calcium fluxes
Mouse nude
[14] Glioma (F98) 50 400 22, 110 entrance dose 0.5, 2.5
Bystander effects in-vivo by clonogenic cell
survival and cellular calcium fluxes
Mouse [15] Mammary (4T1) 1 50 200 150 @5 mm depth
7.5 in a 10 mm solid
water
phantom
Tumour growth, tumour vasculature, and
tumour hypoxia
Mouse [16] Mammary (EMT6.5) 1 25 200 112, 560 NR Immune response by gene expression andhistopathology
Rat [17] Gliosarcoma (9L) 1 50 200 400 entrance dose NR Tumour vasculature, and tumour hypoxia
Rat [18] Gliosarcoma (9L) 1 25 100 625 entrance dose NR Animal survival, tumour growth, andhistopathology
Mouse [19] Squamous cell
carcinoma (SCCVII) 1
35 200 442, 625, 884 entrancedose NR Animal survival, tumour growth, and
tumour ablation
70 200 442 entrance dose
Rat [20] Glioma (C6) 2 25 200 350 entrance dose NR Optic nerve damage by histopathology
Mouse [21] Melanoma (B16F10) 1 50 200 407.6 dose @tumour 6.2 dose @tumour
Tumour growth, tumour vasculature, cell
proliferation, cell senescence, and immune
response
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Table 1. Cont.
Animal Cancer Type Number of Arrays
Microbeam Peak-dose (Gy) Valley-dose (Gy) Evaluated Criteria
Width (µm) Spacing (µm)
Rat [22] Gliosarcoma (9L) 1 25
200 625 entrance dose 12.1 dose @tumour Animal survival, tumour growth, and
histopathology100 625 entrance dose 36 dose @tumour
Rat [23] Gliosarcoma (9L) 1 25 200 625 entrance dose NR Animal survival, tumour growth, andhistopathology
Mouse [24] Mammary (EMT6.5) 1 25 200 560 entrance dose 11
Biochemical changes by synchrotron
Fourier-transform infrared
microspectroscopy
Rat [25] Glioma (C6, F98) 2 25 211 350 entrance dose NR Animal survival and object recognition
Rat [26] Glioma (F98) 2 28 400 350 18 dose @ tumour Animal survival and cognitive dysfunction
Mouse nude
[27] Gliosarcoma (9L) 1 25 211 500 entrance dose 24 (cross-fired)
Animal survival, tumour growth, and
tumour vasculature
Rat [28] Gliosarcoma (9L) 2
25
211
860 entrance dose
18 @1cm depth Animal survival and histopathology50 480 entrance dose
75 320 entrance dose
Rat [29] Gliosarcoma (9L) 3 50 211 400, 360 (+24h), 400(+48h) entrance dose 15 Animal survival and histopathology
Rat [30] Gliosarcoma (9L) 1 27 211 625 entrance dose NR Animal survival, histopathology, andimmune response
Mouse [31] Mammary (EMT6.5) 1 25 200 560 11 Transcriptomics
Mouse nude
[32]
Glioma (U251)
1 100 500 124 4.8
Tumour growth, histopathology, and
apoptosis2
20 100 111 8.2
100 500 124 9.6
Mouse [33] Mammary (EMT6.5) 1 25 200 112, 560 NR Immune response
NR: Not-Reported.
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3.4.6. MRT for non-neoplastic diseases
Microbeam radiation therapy has also been applied to the treatment of several non-malignant
diseases and employed as a tool for studying Central Nervous System (CNS) injury.
Epilepsy:
Due to the high tolerance of the central nervous system to MRT, it has been applied, pre-clinically,
as a radio-surgical tool to modulate brain networks and treat a variety of neurological disorders
including epilepsy. The size and precision of microbeams can mimic a surgical cut to the epileptic
cortex reproducing the current surgical ablation techniques but with a reduced risk of inducing
neurological dysfunction [57,58]. Microbeam transections of the sensorimotor cortex significantly
reduced seizure without inducing neurological dysfunction (100 µm; 400 ctc; 240 or 320 Gy
peak-dose) [59]. This is reflected by decreased neuronal excitability of neurons in the somatosensory
cortex and reduction of spontaneous synaptic activities and synchronization [60]. Anti-epileptic activity
was maintained more than 4 months post-irradiation [61] with an absence of myelin and neurons in
the microbeam-irradiated slices [62].
Restenosis:
MRT has been implemented as a potential treatment for restenosis following angioplasty,
exploiting the vascular-sparing and wound-healing effects of MRT to interfere with the process
of cellular hyperplasia, which underlies this condition [63]. The MRT array used in this study (27 µm;
200 ctc; 150 Gy peak-dose) did not yield significant improvement, and future dose-escalation studies
are required.
Spinal cord Injury:
MRT has also been used as a tool to induce spinal cord injuries to study the mechanisms following
CNS injury [64]. Further studies have been performed, but their microbeams width fall outside our
inclusion criteria.
3.4.7. Normal Tissue Effects of MRT
It has been well described that in addition to effective tumour control, MRT exhibits exceptional
preservation of normal tissues. This tissue-sparing effect is exemplified by the high tolerance of skin,
CNS, and vasculature following MRT doses. Table 2 provides a summary of the conservative MRT
parameters that each publication cites before the onset of pathology in the majority of test animals.
Valley-doses are indicated where provided.
Central Nervous System, Adults:
Slatkin et al. 1995 presented the tissue-sparing effects on normal adult rat brain exposed to MRT
(20 µm; 200 ctc) [18]. Brain tissue appeared normal following peak-dose of 625 Gy, necrosis was absent
even after peak-doses of up to 5000 Gy, and was visible only after a peak-dose of 10000 Gy. In another
study, when multiple arrays were used, brain tissue damage was restricted to the cross-irradiated
regions of the two arrays (25 µm; 200 ctc; 625 Gy peak-dose) and normal tissue damage was absent in
the brain exposed to only one array [25]. Irradiation of the rat spinal cord did not impair locomotion
after 253 Gy (35 µm; 210 ctc), while paresis and foreleg paralysis developed when the dose reached
357 Gy or greater [65]. When valley-doses at the target depth approached 18 Gy (507 Gy peak-dose),
white and grey matter necrosis, necrosis of microvasculature and leukocyte infiltration was observed.
Developing CNS:
Employing MRT in infant patients was also pursued in pre-clinical studies. Early MRT studies were
aimed at assessing its effects on immature brain tissues with suckling rats [26], weanling piglets [66]
Cancers 2020, 12, 527 14 of 26
and unhatched duck embryos [67] as models. In fact, there was a differential dose tolerance of the
suckling rat relative to the weanling piglet, with the rat displaying neurological dysfunction when
exposed to 150 Gy (28 µm; 105 ctc)[26]. Similarly, irradiation of the CNS of the unhatched duck embryo
could withstand a peak-entrance dose of 160 Gy (27 µm; 100 ctc) before displaying signs of ataxia
within 75 days of hatching [67]. In contrast, the piglet showed no signs of neurological damage at
an dose of 600 Gy (28-30 µm; 200 ctc) [66]. These three studies had comparable beam widths, however,
they differed in the beam spacing with 100 µm and 200 µm used in the rat and piglet, respectively.
When the spacing was increased to 200 µm, the dose threshold tolerated by the suckling rat increased
to 300 Gy without signs of neurological dysfunction [26].
Eye:
Certain target areas in the brain may result in ocular radiation exposure. The eye of the rat
developed retinal degeneration after bidirectional MRT arrays (25 µm; 211 ctc; 350 Gy peak-dose) [68].
This may occur after exposure of the retina to valley doses of up to 14 Gy [69]. The optic nerve was
also preserved at these doses [45], however, ocular damage following MRT irradiations to the brain
have not been assessed at doses below 350 Gy. Therefore, a tolerance threshold cannot be reported.
Vasculature:
The normal tissue response and tissue sparing effect of MRT are dependent on the preservation or
regeneration of microvasculature. Vasculature organization of the irradiated tissue depends on the
stage of tissue maturation and as a result, determines tolerance to MRT. Models of immature vasculature
have been the regenerating fin of the zebrafish [70] and the early chick chorioallantoic membrane [71].
The susceptibility of immature vessels to MRT-induced damage is significantly higher than the mature
vessels which show very little post-MRT alterations (vascular lesions, reduced perfusion) when the
MRT spacing is kept below 200 µm [71]. Although conducted in non-malignant tissue, the immature
vasculature is representative of the disorganized, leaky and fast-growing tumour vessel networks.
In the mouse brain, it has been shown that the microvasculature can withstand up to a 1000 Gy
peak entrance dose from a unidirectional MRT array (25 µm; 211 ctc) [72] with only transient
blood-brain-barrier leakage. No vascular damage [73], or changes in cerebral water content were
observed at this dose [72,74]. In the beam path, there is a progressive disappearance of glial and neuronal
cells, but endothelial cells remain detectable in the irradiated tissue and tissue remains perfused.
No changes in blood volume or vascular density are observed (up to 3 months post-irradiation)
indicating rapid vascular repair [72]. Additionally, peripheral arteries in the mouse can tolerate peak
microbeam doses up to 2000 Gy (50 µm; 400 ctc) with minimal damage [75].
Skin:
Studies investigating the tolerance of the skin of rats and mice have shown that doses up to
1170 Gy (90 µm; 300 ctc; dose-valley up to 35 Gy) are marked by the absence of moist desquamation,
focal denudation or exudation [76]. Moreover, 1740–1900 Gy peak-entry-doses showed significant
damage to the skin in both the mouse and the rat with the development of moist desquamation, epilation,
and necrosis. The valley-dose was responsible for these adverse reactions, limiting valley-doses to
less than 45 Gy for both cross-planar MRT of 2 arrays [49] and a single MRT array [76]. The peak
threshold dose is reduced to 650 Gy with a bidirectional microbeam as the volume of irradiated tissue
is increased with this irradiation geometry. The skin has been shown to efficiently repair double-strand
breaks in the microbeam path (24-84 hrs post-irradiation [pi]) with the absence of apoptosis after MRT
(25 µm; 175 ctc) [77]. Doses up to 800 Gy (25 µm; 200 ctc) exhibited similar damage to BB doses of up
to 44 Gy [78]. Histological changes following 800 Gy (25 µm or 50 µm; 200 ctc) include thickening of
the dermis and epidermis, hyperkeratosis, dermal oedema, and a loss of sebaceous glands [6,78].
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Other tissues:
Lastly, MRT has been applied as a fertility-sparing modality for testicular irradiation and has
been able to successfully preserve spermatogenesis in the rat [79]. MRT could, therefore, also be
implemented as a treatment modality for testicular cancers or tumours in the inguinal region where
infertility is an adverse outcome of current conventional radiotherapies.
Importance of Valley-Doses:
Normal brain tissue damage (including radiation-induced necrosis) is highly dependent on the
valley-dose, and many authors suggest that cells in these regions repopulate the tissue damage in those
regions receiving the peak-dose [25,49,66,73,80,81]. Therefore, it is important to ensure that valley-dose
does not exceed the tolerance threshold of the normal tissue [65]. Valley-doses can be reduced either
by decreasing the peak-dose, decreasing the width of the microbeam itself or decreasing the beam
field-size [34]. Delivered MRT doses attenuate with increasing tissue depth [34], with the peak regions
exhibiting a sharper fall-off than the valley regions [82].Ensuring effective dose delivery to the target
while maintaining appropriate valley-doses to preserve normal tissue, is therefore an essential step in
treatment planning. Many papers in the MRT field do not report predicted doses received by the target
tissue, but when provided, these values are reported in Table 2.
Table 2. MRT Parameters Eliciting Normal Tissue Tolerance.
Animal Tissue
Microbeam Pathology Threshold
Peak-Dose (Gy)
Valley-Dose
(Gy)Width (µm) Spacing (µm)
Duck [67] Immature CNS 27 100 Ataxia 160 NR
Rat [15] Brain
27 75 Necrosis, oedema 250 17
27 100 500 33
Rat [73] Brain 27 200 Cell loss, demyelination 1000 NR
Rat [25] Brain 25 100
Tissue damage (loss of tissue
structure; vascular damage)
625 uni- &
bidirectional NR
312 bidirectional
Rat [65] Spinal cord 35 210 Paresis/Paralysis (over 383 dpi) 357 (19mm transversedepth) 12.7
Mouse [72] Brain 25 211
Damage to
microvasculature/vasogenic
oedema (up to 1 mpi)
312–1000 5.8
Rat (11–13
day old) [26] Brain
28 105
Neurological dysfunction
150
>5 Gy [69]
28 105 50
25 210 300 bidirectional
Piglet [66] Brain 20–30 210 Neurological function (465 dpi) 600 peak-entry263 @ cerebellum
12.6 @
cerebellum
Rat [18]
Brain
20 200 Necrosis (14 dpi) 5000
NR
37 75 Tissue damage (14–31dpi) 625
20 200 Loss of nuclei (30-31dpi) 2000
37 75
Skin
37 200 Epilation (2–4 weeks dpi) 1250–2500
37 75 1250–2500
Mouse [74] Brain 25 211 Cerebral oedema (up to 28 dpi) <1000 10.5
Mouse [49] Skin 90 300 Moist desquamation
1740 co-planar 35
650 cross-planar 26
Mouse [76] Skin 90 300 Moist desquamation 1005-1170 14-17
Mouse [83]
Abdomen
25 400
GI syndrome 249 (257 TD50) 7.5 (7.7)
Head Neurological dysfunction 255 (268 TD50) 6.8 (7.2)
Thorax Neurological dysfunction,pulmonary damage
391 (lowest
administered dose) 9.5
Total body Weight loss, moribundbehaviour 88.9 (120 TD50) 2.8 (3.8)
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Table 2. Cont.
Animal Tissue
Microbeam Pathology Threshold
Peak-Dose (Gy)
Valley-Dose
(Gy)Width (µm) Spacing (µm)
Mouse [75] Saphenousartery 50 400
Functional deficits, atrophy,
arterial damage 2000 17.6
Rat [34] Brain 50 211 Neurological dysfunction 480 18
Mouse [79] Testes (ex vivo) 50 100 Spermatogenesis 5 NR
Rat [68] Brain (+eye) 25 211 Retinal degeneration (12 dpi) 350 * (bidirectional) NR
Rat [45] Brain (+eye) 25 200 Optic nerve damage 350 * (bidirectional) NR
Threshold Peak-Dose: indicates the highest peak-dose (skin entry or at indicated tissue depth) reported that did not
result in pathology in the majority of animals. Note: studies testing only one dose are indicated by an asterisk (*).
NR: Not-Reported.
4. Discussion
Conventional RT aims to cure cancer by directly ablating tumorous while selectively sparing
healthy tissues. All modern RT modalities and techniques, ranging from high energy photons to proton
and carbon ions, follow the same paradigm of directly destroying malignant tissue. However, their
success is limited by radiation-induced toxicity to surrounding healthy tissue. This is especially critical
in radiation-resistant tumours, where high, local doses are required for tumour control. MRT, however,
targets tumours and the tumour microenvironment based on a different radiobiological paradigm
(spatial fractionation). Thus, even tumour cells not directly irradiated can be eradicated completely
while damage to healthy tissue can be repaired efficiently. As a consequence, it is anticipated that MRT
will warrant higher tumour control at reduced toxicity in patients.
4.1. Potential Underlying Mechanisms of Microbeam Radiation Therapy
4.1.1. Targeted and Non-Targeted Effects of MRT
Peak-doses cause severe radiation damage that is restricted to the cell populations in the path
of the microbeam. This can be observed in the brain of rats as early as 8h post MRT (25 µm; 200 ctc;
350 Gy peak-dose) [44], and as late as 128 days post MRT (25 µm; 100 ctc; 625 Gy peak-dose) [25].
In the cerebellum of piglets, microbeam tracks were still visible 15 months post MRT (20–25 µm;
211 ctc; cerebellar peak-dose 66 to 263 Gy; valley-dose 3.2 to 12.6 Gy) [66]. Sharp delimitation of
damaged tissue in the microbeam path has also been shown in Drosophila tissue where high peak doses
exceeding lethal, seamless irradiation doses affect specific morphological processes while maintaining
the survival of post-mitotic tissues and the organism as a whole [84].
Radiation-induced bystander effects (RIBE) are relevant for MRT because tissue exposed to
the valley-dose will receive signals from neighbouring cells exposed to the peak-dose. Although
falling outside of our inclusion criteria due to its employment of a single microbeam and not an
array, Dilmanian et al [85] were the first to suggest the importance of RIBE in MRT. Their results
from irradiated rat spinal cord indicated that the repair process and the elimination of apoptotic cells
in the peak area occurred faster than expected, suggesting that restoration and proliferation was a
consequence of “beneficial” bystander factors coming from the valley area. This was further suggested
by the results of experiments by Fernandez-Palomo et al [44] performed in the brain of rats.
When it comes to the effects on non-irradiated tissues (outside of the microbeam array), responses
such as genotoxic effects [77] and clonogenic cell death on cells exposed to signals from the irradiated
animal [19,43] have been observed after MRT. Some of those responses have involved the immune
system [47], with some author suggesting that a functional immune system is key to observe such
genotoxic effects post MRT [86].
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4.1.2. MRT Selectively Disrupts Immature Blood Vessel
The biological effects induced by MRT go beyond direct tumour cell destruction. In fact, MRT
does not impact the morphological and functional characteristics of normal murine brain vessels
even after delivery of doses up to 1000 Gy [72]. Brain perfusion, capillary density and blood volume
remain unaffected 12h to 3 months after an anteroposterior MRT array (25 µm; 211 ctc; 312 or 1000 Gy
peak-entrance dose) [72]. No changes in animal behaviour have been observed [72]. Data from
chick chorioallantoic membrane [71] and zebrafish fin regeneration [70] models demonstrate the
disruptive vascular effect of MRT on immature blood vessels. Work in adult organisms confirmed that
the disruptive vascular effects of MRT depend on the vascular maturation status. In adult zebrafish,
a correlation between microbeam width and biological effects of MRT was identified [70]. The study
indicated that microbeam spacing between 50 to 100 µm could selectively affect mature and immature
vessels. Murine brain vessels do not tolerate beamlets wider than 100µm when peak doses of 400 Gy
are delivered [87]. The use of MRT in rodent models revealed a preferential adverse effect on tumour
vessels rather than those of healthy tissue. In a murine melanoma model, MRT significantly reduced
(24%) the perfusion of the tumour blood vessels indicating vascular disruption [7].
MRT preferentially lowers tumour O2 saturation levels in gliosarcoma as a result of reduced
endothelial cell density and increased inter-vessel distance following two cross-fired arrays
(anteroposterior and lateral; each 50 µm; 200 ctc; 400 Gy peak-entry-dose) leading to tumour hypoxia
observed by GLUT-1 overexpression [32,33,38]. However, the persistence of hypoxia may be dose-,
time- and tumour-dependant with contrasting evidence of tumour hypoxia in a mammary carcinoma
decreasing within 14 days post-irradiation at a dose of 150 Gy [55].
4.1.3. MRT Transiently Increases Tumour Blood Vessel Permeability
Few reports indicate that MRT causes a partial disintegration of the endothelium leading to an
early (1 to 4h) but significant increase in tumour blood vessel permeability (manuscript in preparation).
This “MRT-induced vascular permeability window” represents a potent drug delivery strategy.
Combination of MRT with chemotherapy or nanoparticles applied in the “permeability window”
results in significantly better tumour control (manuscript in preparation). A recently published study
indicated that MRT induced selective vascular permeability in tumour blood vessels but not in
normal vasculature. The tumour vascular permeability was observed from days 2 to 7 after MRT.
In contrast, it was observed only at day 7 after BB radiotherapy [42]. This study also documented
that delivering a second MRT array induced earlier, more pronounced, and more persistent tumour
vascular permeability than BB.
4.1.4. MRT Boosts the Recruitment of Circulating Immune Cells into Tumours
Data obtained in zebrafish indicate that MRT triggers an acute inflammatory response restricted to
the regenerating tissue [70]. Six hours post-MRT, the regenerating tissue was infiltrated by neutrophils,
and thrombocytes which adhered to the cell wall locally in the beam path. The mature tissue was
not affected by microbeam irradiation [70]. In a mouse tumour model, it has been demonstrated
that BB markedly increases tumour-associated macrophages and neutrophils while there were no
increases in these populations following MRT [53]. The role of MRT in the recruitment of immune cells
represents a promising immunoprophylactic treatment strategy and should be further explored in
experimental and clinical studies. A recently performed study in melanoma-bearing animals showed
that MRT (particularly after 2 irradiations) selectively increased production of natural killer (NK) cell-
and cytotoxic T lymphocytes-attracting chemokines while, also showing, decreased secretion of T
regulatory cell-, tumour associated macrophage- and neutrophil-recruiting chemokines (manuscript
in review). The role of single and repeated MRT administration in the recruitment of immune cells
represents a promising immunoprophylactic treatment strategy and should be further explored in
experimental and clinical studies.
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In addition, increased pericyte density following MRT suggests a vascular normalization effect [55]
which may increase migration of immune cell populations to the tumour and modulate cytokine
expression that may support an anti-tumour immune response. Synergism between immunoprophylaxis
and MRT has been documented [39]. Differential modulation of genes involved in inflammation and
immunity are also marked at early timepoints between tumour and normal tissue [29,52] and increased
leukocyte infiltration into the tumour has also been observed.
4.2. Clinical Translation
Barriers to the translation of MRT relate to a limited understanding of how to compare the
radiobiological effects of MRT with conventional BB radiotherapy, as well as, understanding the biology
behind the physical properties of the microbeams. In addition, the optimal therapeutic strategy for
MRT is still to be defined.
4.2.1. Comparative Therapeutic Effects of MRT and BB Radiotherapy
A limited number of studies systematically compared the biological effects of MRT with BB
radiotherapy. The superiority of MRT compared to synchrotron BB treatment for tumour control has
been demonstrated in mice bearing B16-F10 melanoma [7] and rats bearing 9LGS [31]. In these studies,
the MRT valley-dose was kept equal to the BB dose; however, future studies could use the Equivalent
Uniform Dose concept (EUD) to determine more biologically comparable doses of MRT and BB [88].
Dose-escalation studies in healthy rodents have identified doses of MRT and BB predicted to
cause equal rates of late spinal cord myelopathy [65], lethal neurotoxicity [80] and acute toxicity
following total and partial body irradiation [83]. Of these studies, only Smyth et al. [83] included
a comparison between MRT and BB radiotherapy at a conventional dose-rate (in the order of 2 Gy
min−1). This indicates the need for further studies controlling for the potential FLASH tissue-sparing
effects of synchrotron broad-beam irradiation.
4.2.2. Identifying Optimal Targets and Strategies for MRT
A key limitation of MRT is the need for a kilovoltage energy spectrum to maintain spatial
fractionation on a microscopic scale, leading to 30–40% of the dose being attenuated within the first
few centimetres of tissue [89,90]. In addition, the PVDR, which is a metric intrinsically linked to the
therapeutic ratio of MRT, decreases with increasing tissue depth and field size [89]. The majority of
pre-clinical studies to date have been performed in rodent models (Figure 3), where this issue of beam
penetration and PVDR is less important due to the small dimensions of the target. However, human
diseases will require larger field sizes and target depths [91].
Given that PVDRs are likely to be lower for human treatments [91], a strategy which relies on
relatively low peak-dose (100–250 Gy) by leveraging the immunomodulatory [29,53] or angio-disruptive
effects of MRT [42,70] could strike an optimal balance between toxicity and tumour control. Previous
studies have shown MRT to be effective for treating rat models of glioma when combined with
chemotherapeutic agents [36,37,41] or immunotherapy [39]. Future studies should investigate the
optimal dose, sequencing and timing of MRT in relation to chemotherapy and immunotherapy and
whether there is a role for temporally fractionating the delivery of MRT. This is particularly relevant for
combined radio-immunotherapy, where fractionated radiotherapy has been shown to be more effective
than a large single fraction for stimulating an immunogenic response [92,93]. The combination of MRT
with immunotherapy is an under-explored frontier which warrants the attention of future pre-clinical
studies. A previously established model of metastatic melanoma [7] could be ideal in this context,
given the clinical use of radio-immunotherapy for melanoma.
4.2.3. Candidate Animal Models
Animal models for future research should reflect technically feasible and medically justifiable
clinical scenarios for a human trial of MRT. Although various brain malignancies have been the major
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focus of pre-clinical MRT research and proposed as future targets for clinical MRT [94–96], the depth of
intracranial diseases, the need for beams to transverse the skull, and the potential proximity to sensitive
structures could make it a difficult target for the first clinical trials. However, lessons can be learned
from the relatively newer field of FLASH radiotherapy which has already been translated to the clinic
with the first human FLASH treatment being for cutaneous T-cell lymphoma on the forearm [22].
Similarly, superficial or cutaneous lesions, as well as those of the appendicular musculoskeletal
system [96], would be ideal candidates for the first human trials of MRT. Therefore, future animal models
for MRT research could include murine models of cutaneous T-cell lymphoma [97–99], locally recurrent
breast cancer [100], soft-tissue sarcoma [101,102] and osteosarcoma [103–105]. These are diseases which
can be highly radio-resistant and are often refractory to conventional radiotherapy. Ideally, murine
models should be immunocompetent in order to explore and harness the immunomodulatory effects
of MRT. Furthermore, soft-tissue sarcoma and osteosarcoma occur spontaneously in canines and are
well-established models of human disease [106,107]. Veterinary patients would be on a size and scale
more comparable to humans and could provide an intermediate step towards a clinical trial.
4.3. Limitations of this Study
A limitation of this study was that some articles, whose sole purpose was studying the effects of
MRT, fell outside our inclusion criteria because the researchers used a single beam instead of an array.
We would like to report that in one case (properly informed in the text of this scoping review), we cited
one of these articles to complement other animal studies in MRT.
5. Conclusion and Recommendations
5.1. Appropriate Controls
Historically the dose delivered by a synchrotron BB has been considered as a control for MRT.
However, BB originating from synchrotron sources has the potential of achieving FLASH normal tissue
sparing effect. Therefore, the therapeutic advantages of MRT over BB may have been substantially
underestimated in these studies, and appropriate BB irradiation controls, using conventional dose-rates
from clinical linear accelerators or conventional kilovoltage X-ray sources should be used. Additionally,
comparative doses should be based on biological equivalence, such as Equivalent Uniform Dose, rather
than valley-dose alone.
5.2. Standardization of the MRT Array and Doses
Amongst the literature, there is a wide variation in the parameters used for the MRT array and peak
and valley-doses. We recommend working on establishing a method for tracking and standardizing
the effects of these variations. We hope that the two tables presented in this scoping review can serve
as a starting point when selecting radiation parameters for future studies. So that effective tumour
control with effective normal tissue sparing can be achieved. Moreover, progress is needed to identify
the optimal MRT array and doses required for adequate vascular disruption, vascular permeability
and recruitment of tumour-infiltrating immune cells in each animal model.
5.3. Preclinical Animal Models
The most employed tumour models, especially for brain tumours, have been established in rats.
We recommend diversifying the use of animal species and including new tumour cancer models to
accelerate the clinical translation of MRT.
5.4. Veterinary Trials
Veterinary trials, in canines or felines, will provide an important intermediary step between
small, pre-clinical animal models and human treatments. These trials will be crucial to ensure the
radiobiology and physical characteristics of MRT can be translated to humans despite the challenges
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of size and beam attenuation. Furthermore, large animal models will validate a clinical workflow
for MRT, including custom dose-calculation algorithms, conformal treatment planning capabilities,
image-guidance, patient-positioning systems, and reporting and verification of dose coverage of the
target. At this stage, superficial lesions of extremities are the likely first candidates for veterinary trials,
considering their current use in translational research, their prevalence in the canine population and
a favourable anatomic location and depth for MRT.
We believe that the consolidation of these five recommendations may result in a significant
advance and rapid adoption of MRT in the clinic.
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